Intas Pharmaceuticals Ltd.

Rise in prevalence of diseases such as axillary hyperhidrosis in developed countries, expanding product launches and product approvals, and surge in demand. PORTLAND, OR, UNITED STATES, June 9, 2026 / EINPresswire.com / -- Allied Market Research published a report, titled, " Hyperhidrosis Treatment Market by Type (Axillary hyperhidrosis, Palmar hyperhidrosis, Plantar hyperhidrosis, Others), by Treatment (Botulinum toxin injections, Topical treatment, Oral medication), by Age (Below 50 years, Above 50 years): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global hyperhidrosis treatment industry generated $575.3 million in 2021, and is projected to reach $950.7 million by 2031, manifesting a CAGR of 5.1% from 2022 to 2031. Prime determinants of growth - Rise in prevalence of diseases such as axillary hyperhidrosis in developed countries, expanding product launches and product approvals, and surge in demand for improved healthcare services drive the growth of the global hyperhidrosis treatment market. However, lack of awareness and unfavorable reimbursement scenario restrain the market growth. On the other hand, rise in utilization topical treatment and technological advancements present new opportunities in the coming years. Download Sample Report - https://www.alliedmarketresearch.com/request-sample/17972 Covid-19 Scenario The Covid-19 pandemic made a negative impact on the growth of the global hyperhidrosis treatment market. Hospitals either canceled or postponed the hyperhidrosis treatment due to shift in resources toward taking care of Covid-infected patients. However, during the pandemic, many patients carried out treatments on their illnesses using self-medication or other unconventional methods. Patients suffering from hyperhidrosis had a disproportionately larger rate of depression during the Covid-19 pandemic, particularly the female patients. In addition, some of these patients faced difficulties in receiving the therapy during the pandemic. The axillary hyperhidrosis segment to maintain its lead position during the forecast period Based on type, the axillary hyperhidrosis segment accounted for the highest market share in 2021, contributing to around three-fifths of the global hyperhidrosis treatment market, and is projected to maintain its lead position during the forecast period. Moreover, this segment is projected to manifest the largest CAGR of 5.4% from 2022 to 2031. This is due to high incidence of axillary hyperhidrosis among younger as well as adult generation. The report also analyzes the segments including palmar hyperhidrosis, plantar hyperhidrosis, and others. The topical treatment segment to continue its dominant share throughout the forecast period Based on treatment, the topical treatment segment contributed to the highest market share in 2021, accounting for more than three-fifths of the global hyperhidrosis treatment market, and is projected to continue its dominant share throughout the forecast period. Moreover, this segment is estimated to manifest the highest CAGR of 5.4% from 2022 to 2031. This is attributed to product innovation and effective & rapid effects of the topicals. The report also analyzes the segments including botulinum toxin injections and oral medication. The below 50 years segment to continue its highest contribution throughout the forecast period Based on age, the below 50 years segment accounted for the largest market share in 2021, holding around three-fifths of the global hyperhidrosis treatment market, and is estimated to continue its highest contribution throughout the forecast period. In addition, this segment is projected to register the fastest CAGR of 5.3% from 2022 to 2031. This is due to high incidence of hyperhidrosis disease in below 50-year age group. The report also analyzes the above 50 years segment. For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/17972 North America to maintain its leadership status throughout the forecast period Based on region, North America held the largest market share in 2021, accounting for more than two-fifths of the global hyperhidrosis treatment market, and will maintain its leadership status throughout the forecast period. This is attributed to technological advancements in hyperhidrosis treatment, high incidence of disease, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is expected to grow at the largest CAGR of 5.9% from 2022 to 2031, owing to development of healthcare infrastructure and increase in investments projects in the region. Leading Market Players AbbVie Inc. Avanor Healthcare Ltd. Brickbell Biotech, Inc. Dr August Wolff GmbH & Co. Kg Drugs Dr. Reddy's Laboratories Ltd. Eirion Therapeutics, Inc. Eli Lilly and Company Hugel, Inc. Kaken Pharmaceutical Co., Ltd. Intas Pharmaceuticals Ltd. Roivant Sciences Ltd. Theravida, Inc. The report analyzes these key players and highlights various strategies such as new product launches, partnerships, expansion, and others to raise their market penetration and strengthen their position in the market. The report offers a detailed analysis that outlines product portfolio, operating segments, business performance, and key developments of each market player. Similar Research Reports for Information, Communication and Technology: Human Chorionic Gonadotropin (HCG) Market - https://www.alliedmarketresearch.com/human-chorionic-gonadotropin-HCG-market U.S. Intraoperative Neuromonitoring Market - https://www.alliedmarketresearch.com/us-intraoperative-neuromonitoring-market Scaffold Technology Market - https://www.alliedmarketresearch.com/scaffold-technology-market-A11103 Cardiovascular Prosthetic Devices Market - https://www.alliedmarketresearch.com/cardiovascular-prosthetic-devices-market Endotherapy Devices Market - https://www.alliedmarketresearch.com/endotherapy-devices-market About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + + + + + + + + + + + + + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Polpharma Biologics has signed a licensing agreement with Argentina-based Tuteur, granting the Buenos Aires company exclusive commercialization rights across Latin America — excluding Brazil — for PB006, its adalimumab biosimilar targeting autoimmune diseases. Polpharma Biologics, the Switzerland-based biosimilars platform of Poland’s Polpharma Group, will retain full responsibility for development and manufacturing. Financial terms were not disclosed. Regulatory submission in the licensed territory is expected within three years. PB006 is a biosimilar of adalimumab, the fully human IgG1 monoclonal antibody that binds and neutralizes soluble and membrane-bound TNF-α, blocking its interaction with TNF receptors. The reference product, Humira (adalimumab), was originally developed by AbbVie and has been approved across a broad range of autoimmune indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Polpharma describes PB006 as a high-concentration, citrate-free formulation, a design choice associated with reduced injection-site pain relative to citrate-containing adalimumab formulations. Polpharma previously reported PK/PD comparability data for one of its biosimilar programs targeting autoimmune disease, and the company has built out its manufacturing infrastructure through external partnerships, including a strategic cooperation with Chime Biologics announced in April 2025. Under the Tuteur agreement, Tuteur will handle commercialization, marketing, and distribution across the licensed territories; Polpharma Biologics retains all rights outside that geography, including in Brazil, where a separate commercial arrangement with Libbs Farmacêutica covers that market. The deal follows a pattern that has become common in the adalimumab biosimilar segment: a developer retains manufacturing and regulatory control while outsourcing regional commercialization to an established local operator. A structurally comparable arrangement was announced in February 2026, when SteinCares and Shilpa Biologicals struck a licensing agreement to expand biosimilar access across Latin America, combining Shilpa’s development and manufacturing capabilities with SteinCares’ regional commercialization platform — a near-identical division of responsibilities to the Polpharma-Tuteur structure. In the US market, Accord BioPharma similarly secured exclusive licensing rights from Bio-Thera for BAT2506, a proposed golimumab biosimilar, in February 2025, reflecting continued appetite among regional commercial operators for biosimilar in-licensing arrangements. The adalimumab biosimilar space is among the most competitive in biologics. Multiple biosimilars of Humira have been approved in the US and EU, and the LATAM market, while less saturated, is drawing increasing attention from both European and Asian biosimilar developers. The timing of a regulatory submission within three years places PB006’s potential LATAM launch in the late 2020s, a period when several other adalimumab biosimilars may also be seeking or holding regional approvals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

GUANGZHOU, China, May 18, 2026 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced Accord BioPharma received marketing authorization in the United States of America for IMMGOLIS (formerly known as BAT2506), a SIMPONI® (golimumab) biosimilar, for the treatment of adults patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate, and for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The FDA also approved IMMGOLIS INTRI (golimumab-sldi), a biosimilar to Simponi Aria® (golimumab), for the treatment of adult patients with moderately to severely active RA in combination with methotrexate. IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) are the first FDA approved biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab) for rheumatoid arthritis in combination with methotrexate and for ulcerative colitis. Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a pro-inflammatory molecule. Binding of golimumab to TNF-α results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. Bio-Thera signed an exclusive commercialization agreement with Intas on February 10, 2025. Under the agreement, Bio-Thera is responsible for development, manufacturing, and supply of IMMGOLIS and IMMGOLIS INTRI. Accord BioPharma will be responsible for commercializing IMMGOLIS and IMMGOLIS INTRI in the United States of America. "Bio-Thera is proud to have developed the first approved biosimilar of golimumab in the United States of America", said Dr. Shengfeng Li, CEO of Bio-Thera. "We are excited to support Accord BioPharma's commercialization efforts to bring I IMMGOLIS and IMMGOLIS INTRI to patients in need of an affordable biosimilar of golimumab who are living with the chronic, debilitating autoimmune conditions associated with moderately to severely active rheumatoid arthritis or ulcerative colitis." "Our exclusive commercialization agreement with Bio-Thera strengthens our biosimilar pipeline, a vital component of our U.S. growth strategy," said Chrys Kokino, President, North America of Accord. "We're investing heavily in biosimilars through external partnerships plus our own clinical efforts, because we believe in their vast potential to drive patient- and provider-centric solutions. Bio-Thera's global experience makes them an excellent partner." IMMGOLIS is not indicated for and should not be used or administered for the treatment of adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate; adult patients with active ankylosing spondylitis (AS); or pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis (UC). IMMGOLIS INTRI is not indicated for and should not be used or administered for the treatment of Active Psoriatic Arthritis (PsA) in patients 2 years of age and older; Adult patients with active Ankylosing Spondylitis (AS); or Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older. About Bio-Thera Solutions Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including six approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US and USYMRO® (ustekinumab) in EU, IMMGOLISTM and IMMGOLIS INTRITM (golimumab) in US and GOTENFIA® (golimumab) in EU, TOFIDENCE® (tocilizumab) in the US, and AVZIVI® (bevacizumab-tnjn) in the US and in EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera). About Intas Pharmaceuticals Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company headquartered in Ahmedabad, India, with group revenues of USD 2.6 billion. Intas has end-to-end capabilities across formulation development, manufacturing and marketing, including API integration, and strong in-house biosimilar capabilities with more than 15 marketed products. The company operates in 85 countries and employs over 22,000 people. For more information, visit About Accord BioPharma, Inc. Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma believes in the ability of biosimilars to increase access to a number of biologic medicines, that in the past may not have been considered for patients due to their high costs. Accord BioPharma looks forward to providing one of the deepest biosimilar portfolios in the industry. For more information, visit AccordBioPharma.com. Bio-Thera Cautionary Note Regarding Forward-Looking Statements This news release contains certain forward-looking statements relating to IMMGOLIS and IMMGOLIS INTRI (aka BAT2506), or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the company's current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company's views or otherwise. SIMPONI® is a registered trademark of Johnson & Johnson SIMPONI ARIA® is a registered trademark of Johnson & Johnson IMMGOLISTM is a trademark of Accord Biopharma, Inc. IMMGOLIS INTRITM is a trademark of Accord Biopharma, Inc. QLETLI® is a registered trademark of Bio-Thera Solutions, Ltd. BETAGRIN® is a registered trademark of Bio-Thera Solutions, Ltd. STARJEMZA® is a registered trademark of Hikma USYMRO® is a registered trademark of Gedeon Richter GOTENFIA® is a registerd trademark of STADA Arzneimittel AG TOFIDENCETM is a trademark of N.V. ORGANON AVZIVI® is a registered trademark of Sandoz AG POBEVCY® is a registered trademark of Bio-Thera Solutions, Ltd. Contact Bert E. Thomas IV Phone: +1.410.627.1734 Email: [email protected] SOURCE Bio-Thera Solutions, Ltd 21% more press release views with Request a Demo